Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ygal Haupt

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Cell Cycle (Georgetown, Tex.)|June 11, 2004
p53 Regulation: a family affairYgal Haupt
Cell Cycle (Georgetown, Tex.)|April 16, 2003
Certainly no ARFterthought: oncogenic cooperation in ARF induction a key step in tumor suppressionYgal Haupt
F1000Research|December 19, 2017
P53 at the start of the 21st century: lessons from elephantsSue Haupt, Ygal Haupt
Cell Cycle (Georgetown, Tex.)|July 16, 2004
Improving cancer therapy through p53 managementSusan Haupt, Ygal Haupt
Anti-Cancer Drugs|August 24, 2006
Importance of p53 for cancer onset and therapySue Haupt, Ygal Haupt
Frontiers in Oncology|July 28, 2016
Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of OncoproteinsYgal Haupt, Giovanni Blandino
Frontiers in Genetics|March 5, 2021
Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex DisparitySue Haupt, Ygal Haupt
Cell Cycle (Georgetown, Tex.)|January 5, 2012
Mutant p53 subverts PLK2 function in a novel, reinforced loop of corruptionSue Haupt, Ygal Haupt
Methods in Molecular Biology (Clifton, N.J.)|June 26, 2003
Flow cytometric analysis of p53-induced apoptosisMichael Berger, Ygal Haupt
Seminars in Cancer Biology|June 29, 2004
Manipulation of the tumor suppressor p53 for potentiating cancer therapySusan Haupt, Ygal Haupt
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Cell Cycle (Georgetown, Tex.)|June 11, 2004
p53 Regulation: a family affairYgal Haupt
Cell Cycle (Georgetown, Tex.)|April 16, 2003
Certainly no ARFterthought: oncogenic cooperation in ARF induction a key step in tumor suppressionYgal Haupt
F1000Research|December 19, 2017
P53 at the start of the 21st century: lessons from elephantsSue Haupt, Ygal Haupt
Cell Cycle (Georgetown, Tex.)|July 16, 2004
Improving cancer therapy through p53 managementSusan Haupt, Ygal Haupt
Anti-Cancer Drugs|August 24, 2006
Importance of p53 for cancer onset and therapySue Haupt, Ygal Haupt
Frontiers in Oncology|July 28, 2016
Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of OncoproteinsYgal Haupt, Giovanni Blandino
Frontiers in Genetics|March 5, 2021
Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex DisparitySue Haupt, Ygal Haupt
Cell Cycle (Georgetown, Tex.)|January 5, 2012
Mutant p53 subverts PLK2 function in a novel, reinforced loop of corruptionSue Haupt, Ygal Haupt
Methods in Molecular Biology (Clifton, N.J.)|June 26, 2003
Flow cytometric analysis of p53-induced apoptosisMichael Berger, Ygal Haupt
Seminars in Cancer Biology|June 29, 2004
Manipulation of the tumor suppressor p53 for potentiating cancer therapySusan Haupt, Ygal Haupt
Pageof 9